Psilocybin microdosing
Navigating the legal and institutional machinery required to run a Schedule I drug study in healthy volunteers.
Running a microdosing study with a Schedule I substance is only partly a scientific problem. Between 2019 and 2021 I led a small team of research assistants through the logistical and legal structures required to obtain approval to conduct research with psilocybin in healthy volunteers.
That meant sustained communication with multiple U.S. state, federal, and institutional stakeholders — identifying and addressing the ethical, legal, and safety issues in the research proposal, and translating between what the science required and what each regulator needed to see.
The work was supported in part by a Usona Institute Scholarship (2021).
Related writing
Alongside the empirical programme, I have written on the state of the field and on the role of expectancy in psychedelic experience: a review of microdosing research trajectories and practical considerations (Wong & Raz, 2022), and work on suggestibility and psychedelics from therapeutics to social context (Oliver et al., 2024).